Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FINALITY-HF: Finerenone in HFrEF Patients Intolerant or Ineligible for Steroidal MRAs
jRCT2051240264Recruiting
- Sponsor
- CPC Clinical Research
- Start
- Feb 2025
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing Finerenone with Placebo (2 arms). Primary endpoint: Primary composite endpoint. Started Feb 2025; status: recruiting.
02
Drugs
finerenone
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on jRCT2051240264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240264.